Loading clinical trials...
Loading clinical trials...
Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Kite, A Gilead Company
Collaborators
NCT05673967 · Relapsed and Refractory Multiple Myeloma (RRMM)
NCT03683277 · Multiple Myeloma, Relapsed and Refractory Multiple Myeloma, and more
NCT03710915 · Multiple Myeloma, Relapsed and Refractory Multiple Myeloma
NCT03477643 · Relapsed and Refractory Multiple Myeloma
NCT02223598 · Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma
Advanced Cellular Therapeutics Facility, DCAM 0800A
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions